Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37202819/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Discussion: This study will provide more evidence on the effects of NMN on improving sleep quality among patients with chronic insomnia. If proven effective, NMN supplement can be used as a new treatment for chronic insomnia in the future.
Use of Daridorexant among Patients with Chronic Insomnia: A Retrospective Observational Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37176680/
Insomnia is the most prevalent sleep disorder, affecting millions worldwide and taking a heavy toll on patient health with significant social and economic impact. Even though there are multiple different...
Conclusions: These data support the growing awareness that insomnia disorder is heterogeneous and complex. Based on these preliminary results, switching to daridorexant may be a safe and effective treatment alternative for insomnia patients with incomplete or insufficient response to current therapies. Further studies with a longer duration...
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Source : https://www.sciencedirect.com/science/article/pii/S0091302223000146?via=ihub
Orexins (also known as hypocretins) are neuropeptides located exclusively in hypothalamic neurons that have extensive projections throughout the centr...
Summary: Orexins progressively decline during PD and this may contribute to some clinical manifestations of the disease, such as excessive daytime sleepiness. In addition, since orexins play a neuroprotective function over nigral dopaminergic neurons, deficient orexinergic transmission in turn may worsen disease severity and progression. As...
-
Sleep Disorder Connect3yrKey Points • Source: Frontiers in Neuroendocrinology • Conclusions: “In this review, we discuss and update the main preclinical and human studies involving the orexin system with several psychiatric and neurodegenerative diseases. This system Show More
Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS study): study protocol for a multicentric, prospective, randomized controlled clinical trial - Trials
Source : https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07332-x
Background Heart failure with reduced ejection fraction (HFrEF) is associated with sleep dyspnea (SDB), which plays an adverse role in the pathophysiology of the condition. SDB management in HFrEF, however,...
Conclusion: In summary, our RCT will provide data for analyses of the relationship between OSA and dapagliflozin, which may be a potential treatment for sleep apnea.
Sleep as a Therapeutic Target for Pain Management - Current Pain and Headache Reports
Source : https://link.springer.com/article/10.1007/s11916-023-01115-4
Purpose of Review The purpose of this review is to provide a summary of the utilization of sleep as a therapeutic target for chronic pain and to evaluate the recent...
Summary: There is a vast array of investigational opportunities in sleep-targeted therapies for pathologic pain, and larger controlled, prospective trials are needed to fully elucidate their efficacy.